Gossamer Bio Inc. (GOSS) and Galapagos NV (NASDAQ:GLPG) Contrasting side by side

This is a contrast between Gossamer Bio Inc. (NASDAQ:GOSS) and Galapagos NV (NASDAQ:GLPG) based on their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation. The two companies are Biotechnology and they also compete with each other.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Gossamer Bio Inc. 21 -0.25 37.36M -2.32 0.00
Galapagos NV 180 0.00 40.27M -1.69 0.00

In table 1 we can see Gossamer Bio Inc. and Galapagos NV’s gross revenue, earnings per share and valuation.


Table 2 shows Gossamer Bio Inc. and Galapagos NV’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Gossamer Bio Inc. 173,848,301.54% 0% 0%
Galapagos NV 22,320,141.89% 0% 0%

Analyst Ratings

The Ratings and Recommendations for Gossamer Bio Inc. and Galapagos NV are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Gossamer Bio Inc. 0 0 2 3.00
Galapagos NV 0 2 5 2.71

The upside potential is 22.00% for Gossamer Bio Inc. with average price target of $31.5. On the other hand, Galapagos NV’s potential downside is -6.42% and its average price target is $191.29. The data provided earlier shows that Gossamer Bio Inc. appears more favorable than Galapagos NV, based on analyst opinion.

Insider & Institutional Ownership

Roughly 72.1% of Gossamer Bio Inc. shares are held by institutional investors while 16.78% of Galapagos NV are owned by institutional investors. Gossamer Bio Inc.’s share held by insiders are 1.1%.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Gossamer Bio Inc. 6.95% -11.66% 19.08% 0% 0% 10.65%
Galapagos NV -2.84% 32.93% 52.92% 71.36% 55.03% 89.01%

For the past year Gossamer Bio Inc.’s stock price has smaller growth than Galapagos NV.

Galapagos NV, a clinical-stage biotechnology company, develops and commercializes novel medicines in Belgium, Croatia, France, and the Netherlands. The companyÂ’s clinical stage programs include filgotinib, which is in Phase III clinical trial for the treatment of rheumatoid arthritis, CrohnÂ’s disease, and ulcerative colitis; GLPG1690, which is in Phase IIa clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972, which is in Phase 1 clinical trial for the treatment of osteoarthritis; and MOR106 that is in atopic dermatitis (AtD) patients in Phase Ib trial. The company has collaboration agreement with Gilead Sciences, Inc. for the development of filgotinib for inflammatory indications; Servier to develop GLPG1972; and AbbVie for discovery, development, and commercialization of potentiator and corrector molecules for the treatment of cystic fibrosis, as well as with MorphoSys for MOR106. It also has a research and development agreement with Pharnext SA to develop a pipeline of synergistic drug combinations for various indications. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.